This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints, Permissions and Rights Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fisac, C. Articles by Podzamczer, D. Search for Related Content PubMed PubMed Citation Articles by Fisac, C. Articles by Podzamczer, D.

A Comparison of the Effects of Nevirapine and Nelfinavir on Metabolism and Body Habitus in Antiretroviral-Naive Human Immunodeficiency Virus-Infected Patients: A Randomized Controlled Study

Endocrinology (C.F., N.V., C.V.) and Infectious Disease (E.F., M.J.B., E.F., D.P.) Services, Hospital Universitario de Bellvitge, 08907 L’Hospitalet de Llobregat, Barcelona, Spain

Address all correspondence and requests for reprints to: Cesar Fisac, R.D., Endocrinology and Nutrition Service, Hospital Universitario de Bellvitge, c/Feixa Llarga s/n, 08907 L’Hospitalet de Llobregat, Barcelona, Spain. E-mail: cfisac{at}csub.scs.es.

New HIV therapies have significantly increased survival, but are associated with multiple metabolic changes, most of them related to the protease inhibitors (PIs). The objective of this study was to elucidate and compare morphological and metabolic alterations in HIV-infected antiretroviral-naive patients receiving two nucleosides plus the PI nelfinavir (NFV) or the nonnucleoside reverse transcriptase inhibitor nevirapine (NVP). Forty-three patients (NFV, n = 20; NVP, n = 23) receiving 6–12 months of treatment were analyzed. Morphological changes were evaluated by bioelectrical impedance analysis, standard anthropometrics, and clinical examination. Serum total cholesterol (TC), low-density and high- density (HDL-c) lipoprotein cholesterol, triglycerides, glucose, and insulin were determined, among other metabolic parameters. No baseline differences were observed between groups. TC increased in both arms (NVP, 11%; NFV, 17%). HDL-c also increased in both groups, although more markedly in those receiving NVP (44% vs. 20%); on-treatment levels were also elevated (1.57 vs. 1.28 mmol/liter). As a consequence of these changes, the TC/HDL-c ratio dropped by 22% in the NVP arm and remained stable in the NFV group. With the use of NFV, the TC/HDL-c ratio and attendant cardiovascular risk did not change. In contrast, NVP offered benefits regarding lipid status, as manifested by enhanced HDL-c concentrations and decreased TC/HDL-c ratios. Inclusion of NVP should be considered when deciding upon antiretroviral regimens for patients at high coronary risk.

This work was supported in part by Glaxo, Roche, and Boehringer Ingelheim, Spain, by the Fundació August Pi i Sunyer, Spain, and by the Red Tematica Cooperativa de Investigacion en SIDA (Red de grupos 173) del FISss, Spain. It was presented in part at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 2000.

Abbreviations: apo, Apolipoprotein; BMI, body mass index; CVD, cardiovascular disease; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; NFV, nelfinavir; NVP, nevirapine; PI, protease inhibitor; TC, total cholesterol; TG, triglycerides.

This article has been cited by other articles:

				C. Grunfeld, D. P. Kotler, D. K. Arnett, J. M. Falutz, S. M. Haffner, P. Hruz, H. Masur, J. B. Meigs, K. Mulligan, P. Reiss, et al. Contribution of Metabolic and Anthropometric Abnormalities to Cardiovascular Disease Risk Factors Circulation, July 8, 2008; 118(2): e20 - e28. [Full Text] [PDF]

				P. Koutkia, B. Canavan, J. Breu, M. Torriani, J. Kissko, and S. Grinspoon Growth Hormone-Releasing Hormone in HIV-Infected Men With Lipodystrophy: A Randomized Controlled Trial JAMA, July 14, 2004; 292(2): 210 - 218. [Abstract] [Full Text] [PDF]